Ignite Creation Date:
2025-12-25 @ 2:38 AM
Ignite Modification Date:
2026-03-03 @ 2:34 AM
Study NCT ID:
NCT06514534
Status:
RECRUITING
Last Update Posted:
2025-09-22
First Post:
2024-07-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-02-18
Start Date Type:
ACTUAL
Primary Completion Date:
2028-12-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-07-17
First Submit QC Date:
None
Study First Post Date:
2024-07-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-19
Last Update Post Date:
2025-09-22
Last Update Post Date Type:
ESTIMATED